In a report released today, Cedric Besnard from Citi maintained a Buy rating on Haleon PLC (HLN – Research Report), with a price target of £4.00. The company’s shares closed yesterday at p369.60.

In a report released today, Iain Simpson from Barclays maintained a Buy rating on Haleon PLC (HLN – Research Report), with a price target of £4.45. The company’s shares closed yesterday at ...

Investing.com -- Moody's Ratings has upgraded the long-term issuer rating of Haleon plc and its guaranteed subsidiaries to A3 from Baa1. The rating agency also upgraded the rating on Haleon's ...

(Bloomberg) -- Pfizer Inc. raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon Plc, culminating a years-long separation from the maker of Sensodyne ...

(Reuters) -Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share ...

Pfizer (NYSE:PFE) has generated £2.5B ($3.24B) after selling its entire stake in Haleon (NYSE:HLN), the consumer healthcare company it established with the British pharmaceutical giant GSK (GSK ...

LONDON - Haleon plc (LSE/NYSE: HLN), a global leader in consumer health, has announced an agreement with Pfizer Inc. (NYSE:PFE) to buy back approximately £170 million worth of its ordinary shares.

Pfizer sold its remaining 7.3% stake in Haleon for $3.1 billion, fully exiting its position in the company. Haleon expects 2025 organic revenue growth of 4% to 6%, with stronger performance in the ...

March 19 (Reuters) - Drugmaker Pfizer (PFE.N), opens new tab has sold its entire stake in Haleon (HLN.L), opens new tab for about 2.5 billion pounds ($3.24 billion) to institutional investors and ...